Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

NCT03620019 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Melanoma Stage Iii
Melanoma Stage Iv
Melanoma
Melanoma (Skin)
Cutaneous Melanoma

Interventions

DRUG: Denosumab
DRUG: Pembrolizumab
DRUG: Nivolumab

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]